Hansa Biopharma AB has entered into a U.S. convertible note purchase agreement with funds managed by Athyrium Capital Management totaling $30M in aggregate principal amount of unsecured convertible senior notes. The company stated that the financing extends its cash runway into mid‑2027 and is intended to support a planned U.S. launch of imlifidase, subject to regulatory approval.
The notes have a maturity date of March 17, 2031 and carry a fixed annual interest rate of 3 percent. Interest will be paid in cash on a semi‑annual basis, beginning on September 15, 2026. The conversion premium is set at 25 percent over the 30‑day volume‑weighted average price per ordinary share ending on March 18, 2026.
According to Hansa Biopharma’s CEO, the financing is expected to provide the resources required to execute a U.S. launch plan for imlifidase. Athyrium Capital Management said the capital is being provided in support of the planned U.S. commercial launch of the product and highlighted what it views as the potential for imlifidase to address unmet needs in highly sensitized patients on kidney transplant waiting lists.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!